查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1968154

全球患者來源異種移植模型市場規模、佔有率、趨勢和成長分析報告（2026-2034）

Global Patient-Derived Xenograft Model Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 138 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

患者來源的異種移植模型市場預計將從 2025 年的 3.3513 億美元成長到 2034 年的 7.9997 億美元，2026 年至 2034 年的複合年成長率為 10.15%。

隨著製藥和生物技術公司專注於個人化醫療，全球患者來源異種移植（PDX）模型市場正穩步成長。 PDX模型是透過將人類腫瘤組織移植到免疫力缺乏小鼠體內而建構的，有助於研究人員更精確地研究癌症行為。全球癌症病例的不斷增加以及對有效標靶治療的需求是推動市場成長的主要因素。此外，對腫瘤學研究和藥物研發計畫的投入不斷增加，也促進了PDX模型的應用。

推動這一市場發展的關鍵因素之一是對能夠忠實再現人類腫瘤生物學的可靠臨床前模型的需求日益成長。傳統的細胞株模型往往無法準確預測臨床結果，而PDX模型則能更好地揭示藥物反應。精準醫療舉措的擴展以及學術機構與製藥公司之間的合作也促進了這一需求。政府對癌症研究的資助進一步推動了先進研究模型的開發和應用。

未來幾年，隨著人源化小鼠模型的發展和移植技術的進步，市場預計將持續成長。將基因組分析和生物標記分析整合到PDX平台將進一步提升其在藥物研發中的價值。新興市場醫療保健投資的增加也有望推動市場成長。總而言之，持續創新和對腫瘤學研究的重視將為該市場帶來未來的成長機會。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球病患來源異種移植模型市場：依腫瘤類型分類

  • 市場分析、洞察與預測
  • 肺癌
  • 胰臟癌
  • 攝護腺癌
  • 乳癌
  • 其他

第5章：全球病患來源異種移植模型市場：依模型類型分類

  • 市場分析、洞察與預測
  • 小鼠模型
  • 大鼠模型

第6章：全球病患來源異種移植模型市場：依最終用途分類

  • 市場分析、洞察與預測
  • 製藥和生物製藥公司
  • 學術研究機構
  • CRO 和 CDMO

第7章 全球病人來源異種移植模型市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第8章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第9章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Charles River Laboratories
    • The Jackson Laboratory
    • Crown Bioscience
    • Altogen Labs
    • Envigo
    • WuXi AppTec
    • Oncodesign
    • Hera Biolabs
    • XenTech
    • Abnova Corp
簡介目錄
Product Code: VMR112110348

The Patient-Derived Xenograft Model Market size is expected to reach USD 799.97 Million in 2034 from USD 335.13 Million (2025) growing at a CAGR of 10.15% during 2026-2034.

The Global Patient-Derived Xenograft (PDX) Model Market is growing steadily as pharmaceutical and biotechnology companies focus more on personalized medicine. PDX models are created by implanting human tumor tissues into immunodeficient mice, which helps researchers study cancer behavior more accurately. The rising number of cancer cases worldwide and the demand for effective targeted therapies are major factors supporting market growth. In addition, increasing investment in oncology research and drug discovery programs is boosting the use of PDX models.

One of the key drivers of this market is the growing need for reliable preclinical models that closely replicate human tumor biology. Traditional cell-line models often fail to predict clinical outcomes accurately, whereas PDX models provide better insights into drug response. The expansion of precision medicine initiatives and collaborations between academic institutions and pharmaceutical companies are also contributing to demand. Government funding for cancer research further supports the development and adoption of advanced research models.

In the coming years, the market is expected to expand with advancements in humanized mouse models and improved transplantation techniques. The integration of genomic profiling and biomarker analysis with PDX platforms will enhance their value in drug development. Emerging markets are also likely to witness growth due to increasing healthcare investments. Overall, continuous innovation and strong focus on oncology research will create promising future opportunities for this market.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Tumor Type

  • Lung Cancer
  • Pancreatic Cancer
  • Prostate Cancer
  • Breast Cancer
  • Others

By Model Type

  • Mice Model
  • Rat Model

By End Use

  • Pharmaceutical and Biopharmaceutical Companies
  • Academic and Research Institutes
  • CROs and CDMOs

COMPANIES PROFILED

  • Charles River Laboratories, The Jackson Laboratory, Crown Bioscience, Altogen Labs, Envigo, WuXi AppTec, Oncodesign, Hera Biolabs, XenTech, Abnova Corp
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL PATIENT-DERIVED XENOGRAFT MODEL MARKET: BY TUMOR TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Tumor Type
  • 4.2. Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Pancreatic Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Prostate Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PATIENT-DERIVED XENOGRAFT MODEL MARKET: BY MODEL TYPE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Model Type
  • 5.2. Mice Model Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Rat Model Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PATIENT-DERIVED XENOGRAFT MODEL MARKET: BY END USE 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast End Use
  • 6.2. Pharmaceutical and Biopharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Academic and Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. CROs and CDMOs Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PATIENT-DERIVED XENOGRAFT MODEL MARKET: BY REGION 2022-2034(USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Tumor Type
    • 7.2.2 By Model Type
    • 7.2.3 By End Use
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Tumor Type
    • 7.3.2 By Model Type
    • 7.3.3 By End Use
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Russia
    • 7.3.9 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Tumor Type
    • 7.4.2 By Model Type
    • 7.4.3 By End Use
    • 7.4.4 India
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 Australia
    • 7.4.8 South East Asia
    • 7.4.9 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Tumor Type
    • 7.5.2 By Model Type
    • 7.5.3 By End Use
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 South East Asia
    • 7.5.9 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Tumor Type
    • 7.6.2 By Model Type
    • 7.6.3 By End Use
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL PATIENT-DERIVED XENOGRAFT MODEL INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 Charles River Laboratories
    • 9.2.2 The Jackson Laboratory
    • 9.2.3 Crown Bioscience
    • 9.2.4 Altogen Labs
    • 9.2.5 Envigo
    • 9.2.6 WuXi AppTec
    • 9.2.7 Oncodesign
    • 9.2.8 Hera Biolabs
    • 9.2.9 XenTech
    • 9.2.10 Abnova Corp